Research Papers:

Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men

James R. Marshall, Raymond F. Burk, Rochelle Payne Ondracek, Kristina E. Hill, Marjorie Perloff, Warren Davis, Roberto Pili, Saby George and Raymond Bergan _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:26312-26322. https://doi.org/10.18632/oncotarget.15460

Metrics: PDF 2514 views  |   HTML 3583 views  |   ?  


James R. Marshall1, Raymond F. Burk2, Rochelle Payne Ondracek1, Kristina E. Hill2, Marjorie Perloff3, Warren Davis1, Roberto Pili4, Saby George1, Raymond Bergan5

1Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY 14263, USA

2Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, C2104 Medical Center North, Nashville, TN 37232, USA

3National Cancer Institute, Bethesda, MD 20892, USA

4Department of Medicine, Indiana University School of Medicine, R3 C516, Indianapolis, IN 46202, USA

5Knight Cancer Institute, Oregon Health Sciences University, Portland, OR 97239, USA

Correspondence to:

James R. Marshall, email: [email protected]

Keywords: selenium, selenomethionine, methyl selenocysteine, chemoprevention, pharmacokinetics

Received: December 01, 2016     Accepted: February 06, 2017     Published: February 17, 2017


According to the Nutritional Prevention of Cancer (NPC) trial, a selenized yeast supplement containing selenium, 200 mcg/day, decreased the incidence of total cancer, cancers of the prostate, colon and lung, and cancer mortality. The active agent in the selenized yeast supplement was assumed to be selenomethionine (SEMET), although the supplement had not been well speciated. The SELECT study, largely motivated by the NPC trial, enrolling nearly 40 times as many subjects, showed unequivocally that selenium 200 mcg/day, with selenium in the form of SEMET, does not protect selenium-replete men against prostate or other major cancer. The agent tested by SELECT, pure SEMET, could have been different from the selenized yeast tested in NPC. One of the selenium forms suspected of having chemopreventive effects, and which may have been present in the NPC agent, is methyl selenocysteine (MSC). This study, with 29 selenium-replete patients enrolled in a randomized, double-blind trial, compared the multiple-dose toxicity, pharmacokinetics and pharmacodynamics of MSC and SEMET. Patients were on trial for 84 days. No toxicity was observed. Although SEMET supplementation increased blood selenium concentration more than MSC did, neither form had a more than minimal impact on the two major selenoproteins: selenoprotein P(SEPP1) and glutathione peroxidase(GPX).

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15460